[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100389548":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":16,"responsibleParty":74,"collaborators":10,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":10,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":98,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Participants Treated With Glecaprevir\u002FPibrentasvir (GLE\u002FPIB)",null,"Participants will receive GLE\u002FPIB over 8 weeks of therapy as prescribed by their physicians.",[13],{"name":14,"affiliation":5,"role":15},"ABBVIE INC.","STUDY_DIRECTOR",[17,29,38,47,56,65],{"facility":18,"status":10,"city":19,"state":10,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":10},"South Ural State Medical University \u002FID# 225501","Chelyabinsk","454052","Russia","RU",{"type":24,"coordinates":25},"Point",[26,27],61.42877,55.1611,{"lat":27,"lon":26},{"facility":30,"status":10,"city":31,"state":10,"zip":32,"country":21,"countryCode":22,"cosmosGeoPoint":33,"geoPoint":37,"contacts":10},"Irkutsk Regional Center for the Prevention and Control of AIDS and Infections \u002FID# 225499","Irkutsk","664035",{"type":24,"coordinates":34},[35,36],104.29076,52.29566,{"lat":36,"lon":35},{"facility":39,"status":10,"city":40,"state":10,"zip":41,"country":21,"countryCode":22,"cosmosGeoPoint":42,"geoPoint":46,"contacts":10},"S. P. Botkin City Hospital \u002FID# 225500","Oryol","302038",{"type":24,"coordinates":43},[44,45],36.0791,52.96879,{"lat":45,"lon":44},{"facility":48,"status":10,"city":49,"state":10,"zip":50,"country":21,"countryCode":22,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Samara Region Clinical HIV\u002FAIDS Prevention and Control Center \u002FID# 222582","Samara","443029",{"type":24,"coordinates":52},[53,54],50.13553,53.20767,{"lat":54,"lon":53},{"facility":57,"status":10,"city":58,"state":10,"zip":59,"country":21,"countryCode":22,"cosmosGeoPoint":60,"geoPoint":64,"contacts":10},"Stavropol State Medical University \u002FID# 226589","Stavropol","355017",{"type":24,"coordinates":61},[62,63],41.9642,45.03442,{"lat":63,"lon":62},{"facility":66,"status":10,"city":67,"state":10,"zip":68,"country":21,"countryCode":22,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Medical center Academy \u002FID# 226587","Ulyanovsk","432063",{"type":24,"coordinates":70},[71,72],48.38657,54.32824,{"lat":72,"lon":71},{"type":75,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100389548","efficacy-study-of-oral-glecaprevirpibrentasvir-tablet-in-pediatric-12-years-and-older-and-adult-treatment-naive-participants-with-chronic-hepatitis-c-genotypes-1-to-6-and-liver-cirrhosis-100389548",false,"NCT04352309","Efficacy Study Of Oral Glecaprevir\u002FPibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis","REAl World Evidence Of The Effectiveness And Clinical Practice Use Of Glecaprevir\u002FPibrentasvir For 8 Weeks Treatment In Patients With Chronic HepatitiS C GenotYpes 1 to 6 And Liver Cirrhosis In Russian Federation (EASY)","EASY","Inclusion Criteria:\n\n* Treatment-naïve male or female with confirmed CHC, genotypes 1, 2, 3, 4, 5, or 6, with compensated liver cirrhosis, receiving combination therapy with the all oral GLE\u002FPIB regimen for 8 weeks according to standard of care, international guidelines and in line with the current local label.\n* Participants may be enrolled up to 4 weeks after treatment initiation.\n\nExclusion Criteria:\n\n* Participating or intending to participate in a concurrent interventional therapeutic trial.","ALL","12 Years",{"count":87,"type":88},99,"ACTUAL","OBSERVATIONAL","Hepatitis C Virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged. This can lead to cirrhosis (scarring of the liver) and liver cancer leaving trial participants with need for liver transplant. The purpose of this study is to see how effective Glecaprevir\u002FPibrentasvir (GLE\u002FPIB) is in a real world setting of participants with chronic HCV genotypes 1 to 6 and liver cirrhosis who have never received any treatment for HCV.\n\nGLE\u002FPIB is a drug developed for the treatment of HCV infection. This is a prospective (future), observational study in treatment-naive (those who have not received treatment) participants with HCV genotypes 1 to 6 and compensated cirrhosis. All study participants will receive GLE\u002FPIB as prescribed by their study doctor in accordance with approved local label. Pediatric (12 years and older) and adult participants with a diagnosis of HCV genotypes 1 to 6 and compensated cirrhosis will be enrolled in the study in Russian Federation.\n\nParticipants will receive GLE\u002FPIB tablets to be taken by mouth daily according to their physicians' prescription. The total duration of the study is 20 weeks, with a treatment period of 8 weeks and a follow up period of 12 weeks.\n\nThere is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 12 weeks.",[92],"Hepatitis C Virus (HCV)",[94,95,96,97],"HCV, Hepatitis C Virus","Hepatitis C","Liver Cirrhosis","GLE\u002FPIB","COMPLETED","2022-06-08",{"date":101,"type":88},"2022-06-09",{"date":103,"type":88},"2020-05-29",{"date":105,"type":88},"2021-06-11",{"name":5,"class":6},6]